Denver, CO – According to filings with the U.S. Securities and Exchange Commission, Cerecin is raising $14,999,935.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Charles Stacey played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Cerecin

Cerecin is a healthcare company with almost 20 years of innovation and leadership in brain health. We develop novel evidence-based therapeutics and products that aim to help millions of people. These solutions are designed to target conditions ranging from memory impairment to Alzheimer’s disease and other devastating neurological diseases. Cerecin is a global company headquartered in Singapore and the USA and our therapies are developed for persons around the world.

To learn more about Cerecin, visit http://www.cerecin.com/

Contact:
Charles Stacey, President and Chief Executive Officer
303-999-3700
https://www.linkedin.com/in/cstacey/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved